Exelixis, Inc. (EXEL)
Nasdaq: EXEL · Biological Products, (No Diagnostic Substances) · Alameda, CA · filing with the SEC since 2000
Grade7.5
◀ Past 8.6● Present 8.5▶ Future 5.1
Filings
305 filings since 2017 beside 803 insider forms · Large accelerated filer · read from EDGAR on Nov 13, 2026Due nextLarge accelerated filer
10-K
Annual report for the fiscal year ending Jan 1, 2027Large accelerated filers have 60 days after the fiscal year ends.
by Mar 2, 2027
10-Q
Quarterly report for the quarter ending Apr 30, 2027Large accelerated filers have 40 days after the quarter ends; quarter ends are taken to the month end.
by Jun 9, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 27 days after the quarter ended. The proxy statement was last filed Apr 15, 2026.
Filings a yearinsider forms included
1261251108112511711991
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 8 times in the last 36 months, the newest May 29, 2026.SEC letters: 5 in the last 36 months, the newest May 21, 2024.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
May 29, 2026
8-K items 5.02, 5.07, 9.01
Officer or director change; Shareholder vote · Current report
May 26, 2026
Nov 7, 2025
8-K items 5.02, 8.01
Officer or director change; Other event · Current report
Nov 4, 2025
40 of 305 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.